Background: Asthma and other chronic airway diseases can be effectively treated by inhaler therapy. Inhaler therapy depends on appropriate use of the inhaler. This study evaluates the knowledge among Dutch children and their parents regarding asthma inhaler therapy and appropriateness of its use.

Findings: Five general practices selected all children aged 0 to 12 years on asthma inhalation medication. Children demonstrated inhaler use and were interviewed with their parents.46 subjects were enrolled; mean age 5.5 years (SD 3.4) years; 26 (57%) were boys. Of the children using one inhaler only, 70% used the inhaler as indicated and of those using more than one inhaler 46%. On average 2.6 mistakes were made during demonstration of the technique, and 2 mistakes were reported in the interview. In total, 87% of the parents decided when and how the inhaler had to be used. Spacer cleaning was performed correctly by 49%; 26% reported a correct way of assessing how many doses were remaining.

Conclusion: Dutch children make essential mistakes related to inhaler use that are easy to avoid. We recommend a better explanation and demonstration of the technique, and recommend involvement of the parents during instruction.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2718905PMC
http://dx.doi.org/10.1186/1756-0500-2-129DOI Listing

Publication Analysis

Top Keywords

inhaler therapy
12
inhaler
10
asthma inhalation
8
inhalation medication
8
medication children
8
involvement parents
8
dutch children
8
demonstration technique
8
children
6
adequate asthma
4

Similar Publications

Background: Guidelines specify steroids as therapy for acute exacerbation of chronic obstructive pulmonary disease (AECOPD). However, the duration of survival benefit associated with steroids and the optimal dosage of nebulized budesonide (NB) during hospitalization remain unclear.

Methods: We conducted a retrospective study of hospitalized AECOPD patients.

View Article and Find Full Text PDF

Objective: This integrative review aims to evaluate the efficacy and safety of nebulized tranexamic acid (TXA) in managing hemoptysis, assessing its potential as a non-invasive alternative to traditional invasive procedures.

Methods: An integrative review was conducted in accordance with PRISMA guidelines and was registered on PROSPERO (CRD42024584812). The search included databases such as PubMed, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials, encompassing studies published up to August 7, 2024.

View Article and Find Full Text PDF

PDE4 Inhibitors and their Potential Combinations for the Treatment of Chronic Obstructive Pulmonary Disease: A Narrative Review.

Open Respir Med J

November 2024

New Drug Discovery Research, Mankind Research Centre, Mankind Pharma Limited, Plot No 191-E, Sector 4-II, IMT Manesar, Gurugram, India-122051.

Chronic Obstructive Pulmonary Disease (COPD) is associated with cough, sputum production, and a reduction in lung function, quality of life, and life expectancy. Currently, bronchodilator combinations (β2-agonists and muscarinic receptor antagonists, dual therapy) and bronchodilators combined with inhaled corticosteroids (ICS), triple therapy, are the mainstays for the management of COPD. However, the use of ICS in triple therapy has been shown to increase the risk of pneumonia in some patients.

View Article and Find Full Text PDF

The term "asthma-chronic obstructive pulmonary disease (COPD) combined phenotype" describes patients with persistent airflow limitation and features of both asthma and COPD. There is a lack of data on effective treatments for this group, often excluded from asthma or COPD trials. Inhaled corticosteroids (ICS) are standard for asthma, while bronchodilators are key for COPD.

View Article and Find Full Text PDF

Background: Inhaled corticosteroids (ICS) are recommended treatment for mild asthma. We aimed to update the evidence on the efficacy and safety of ICS-containing regimens, leukotriene receptor antagonists (LTRA), and tiotropium relative to as-needed (AN) short-acting β2-agonists (SABA) in children (aged 6-11 years) and adolescents/adults.

Methods: A systematic review of randomized controlled trials (RCTs) of regular and AN treatment for mild asthma was conducted (CRD42022352384).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!